Recommendations for Aduhelm require more guidance and an expanded clinical profile to address several issues that will aid in discussions between patients and providers, per a systematic review of clinical data published in Neurology.
“The approval of aducanumab marks a shift in AD therapeutics from medications targeting symptoms (eg, acetylcholinesterase inhibitors) to those targeting neuropathology associated with AD,” Gregory S. Day, MD, of the department of neurology at the Mayo Clinic, and colleagues wrote. “Whether aducanumab will result in a clinically meaningful